A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis

NCT05447260 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

87

Enrollment

OTHER

Sponsor class

Conditions

Myelofibrosis

Interventions

DRUG: Ruxolitinib

Sponsor

Qilu Hospital of Shandong University